Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY, United States.
Samuel J. Wood Library & C.V. Starr Biomedical Information Center, Weill Cornell Medicine, New York, NY, United States.
Int J Cardiol. 2018 Jun 15;261:42-46. doi: 10.1016/j.ijcard.2017.12.071.
Totally endoscopic coronary artery bypass (TECAB) has emerged as an alternative to other minimally invasive techniques. However, limited TECAB results are available to date. The purpose of this systematic review is to examine the existing literature to give an objective estimate of the outcomes of TECAB using a meta-analytical approach.
A comprehensive online review was performed in Ovid MEDLINE®, Ovid EMBASE and The Cochrane Library from 2000 to July 2017. Eligible studies included single arm TECAB studies as well as comparative studies (TECAB vs minimally invasive direct coronary artery bypass (MIDCAB)). Pooled event rates and odds ratios (ORs) for operative mortality, perioperative myocardial infarction (MI), perioperative stroke, graft patency and repeat revascularization were estimated. Single arm and pairwise comparisons were performed.
Seventeen single arm TECAB articles (3721 patients, weighted mean follow-up 3.3years) were included. The pooled event rate was 0.80% (95%CI: 0.60-1.2%) for operative mortality, 2.28% (95%CI: 1.7-3%) for perioperative MI, 1.50% (95%CI: 1.1-2.0%) for perioperative stroke, 2.99% (95%CI: 1.6-5.4%) for repeat revascularization and 94.8% (95%CI: 89.3-97.5%) for early graft patency (weighted mean follow-up 10.1months). On pairwise meta-analysis 376 patients (263 TECAB and 113 MIDCAB) were included. No difference in operative mortality (OR=0.25, 95%CI: 0.02-2.83), perioperative MI (OR=3.09, 95%CI: 0.37-26.12) or perioperative stroke (OR=1.33, 95%CI: 0.17-10.26) was found between the two techniques.
TECAB has an acceptably low operative risk and a good early patency rate. The incidence of perioperative MI requires further investigation. The dearth of data comparing TECAB to open approaches compels the need for future comparative trials.
全内窥镜冠状动脉旁路移植术(TECAB)已成为其他微创技术的替代方法。然而,目前有限的 TECAB 结果。本系统评价的目的是通过荟萃分析方法,检查现有文献,对 TECAB 的结果进行客观评估。
从 2000 年到 2017 年 7 月,在 Ovid MEDLINE®、Ovid EMBASE 和 The Cochrane Library 中进行了全面的在线检索。合格的研究包括单臂 TECAB 研究和对照研究(TECAB 与微创直接冠状动脉旁路移植术(MIDCAB))。估计手术死亡率、围手术期心肌梗死(MI)、围手术期卒中、移植物通畅率和再次血运重建的合并事件率和优势比(ORs)。进行了单臂和配对比较。
纳入了 17 篇单臂 TECAB 文章(3721 例患者,加权平均随访 3.3 年)。手术死亡率的合并发生率为 0.80%(95%CI:0.60-1.2%),围手术期 MI 为 2.28%(95%CI:1.7-3%),围手术期卒中为 1.50%(95%CI:1.1-2.0%),再次血运重建为 2.99%(95%CI:1.6-5.4%),早期移植物通畅率为 94.8%(95%CI:89.3-97.5%)(加权平均随访 10.1 个月)。在成对荟萃分析中,纳入了 376 例患者(263 例 TECAB 和 113 例 MIDCAB)。两种技术之间的手术死亡率(OR=0.25,95%CI:0.02-2.83)、围手术期 MI(OR=3.09,95%CI:0.37-26.12)或围手术期卒中(OR=1.33,95%CI:0.17-10.26)无差异。
TECAB 具有可接受的低手术风险和良好的早期通畅率。围手术期 MI 的发生率需要进一步调查。缺乏比较 TECAB 与开放方法的数据,这迫使需要未来进行比较试验。